Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced an update on Phase 1 dose escalation data of ARV-471, a novel PROTAC® estrogen receptor (ER) degrader, which is being co-developed for the treatment of patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-). These data were […]
Pfizer: Arvinas And Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues To Demonstrate Encouraging Clinical Benefit Rate In Patients With Locally Advanced Or Metastatic ER+/HER2- Breast Cancer
- Post author:admin
- Post published:December 13, 2021
- Post category:Uncategorized
Tags: Education News